NCT07299175

Brief Summary

Primary aim: evaluate the effect of MITA application on language improvement in children with Autism. Secondary aim: evaluate the effect of MITA application on sociability and cognitive awareness in children with Autism.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2021

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

September 20, 2024

Completed
1.3 years until next milestone

First Posted

Study publicly available on registry

December 23, 2025

Completed
Last Updated

December 23, 2025

Status Verified

December 1, 2025

Enrollment Period

2.3 years

First QC Date

September 20, 2024

Last Update Submit

December 9, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • evaluate the effect of MITA application on language improvement in children with Autism.

    evaluation through :Autism Treatment Evaluation Checklist and Mental Synthesis Evaluation Checklist.

    baseline , after 3 months and after 6 months .

Interventions

If an application called Mental Imagery Therapy for Autism (MITA) has an effect on language improvement,sociability and cognitive awareness in a sample of children with Autism to seek to provide a tablet-based therapeutic application as a means of reducing the therapy gap and improve quality of care .

Eligibility Criteria

Age8 Years - 8 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

A sample of Children with ASD who were diagnosed by Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria.

You may qualify if:

  • Age: 2 year to 8 years.
  • Both sexes
  • Diagnosed with autism spectrum disorders

You may not qualify if:

  • A history of other developmental disorders or neuropsychiatric disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University

Cairo, Egypt

Location

MeSH Terms

Conditions

Autism Spectrum Disorder

Condition Hierarchy (Ancestors)

Child Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Study Officials

  • Mohamed Abd EL-Adl El-Sawy, Professor of Pediatrics

    Professor of Pediatrics ain shams university

    STUDY CHAIR
  • Ola Ali Khalifa, professor

    professor of medical genitics ain shams university

    STUDY DIRECTOR
  • Azza Mohamed Youssef, professor

    Professor of developmental and behavioral pediatrics ain shams university

    STUDY DIRECTOR
  • Asmaa Wafeek Abdelaziz, assistant professor

    assistant prfessor of pediatrics ain shams university

    PRINCIPAL INVESTIGATOR
  • Sarah Farid Mohamed Fahmy, Associate Proffessor

    associate Professor of clinical pharmacy ain shams university

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Master student in Pediatric Department

Study Record Dates

First Submitted

September 20, 2024

First Posted

December 23, 2025

Study Start

October 1, 2021

Primary Completion

January 1, 2024

Study Completion

May 1, 2024

Last Updated

December 23, 2025

Record last verified: 2025-12

Locations